Low levels of MITF are associated with invasion, enhanced tumor-initiating capacity (Carreira et al., 2006; Cheli et al., 2012), as well as with drug-resistant and slow-cycling phenotypes (Konieczkowski et al., 2014; Müller et al., 2014; Dugo et al., 2015; Rambow et al., 2018). This evidence concerns the gene MITF and neoplasm.